Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain.
A random group of 50 patients in tumor stages T1-3N0-2M0 was selected from breast cancer patients and given Ukrain therapy by intravenous injection. Twenty-five patients received a total dose of 50 mg Ukrain (5 mg every second day, 10 injections altogether). Twenty-five patients received a total dose of 100 mg Ukrain (10 mg every second day, 10 injections altogether).
Uglyanitsa
K N
KN
Oncology Department of Grodno Higher Medical School, Grodno, Belarus.
Nefyodov
L I
LI
Karayedova
L M
LM
Nowicky
J W
JW
Brzosko
W
W
D000470:Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001600:Berberine Alkaloids; D001772:Blood Cell Count; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007275:Injections, Intravenous; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D009243:NAD / Q000378:metabolism; D010617:Phenanthridines
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D001600:Berberine Alkaloids; D010617:Phenanthridines; D009243:NAD; C060921:ukrain